Brian Piekos - 18 Oct 2021 Form 4 Insider Report for Gemini Therapeutics, Inc. /DE (IRON)

Reporting relationship: Chief Financial Officer
Issuer ticker: IRON
Reported as of: 18 Oct 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Oct 2021, 17:49:59 UTC
Prior SEC filing: 18 May 2021
Next SEC filing: 14 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Jason Meyenburg, attorney-in-fact

Key filing fact

Brian Piekos filed Form 4 for Gemini Therapeutics, Inc. /DE (IRON) on 20 Oct 2021.

Key facts

This page summarizes Brian Piekos's Form 4 filing for Gemini Therapeutics, Inc. /DE (IRON).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Oct 2021, 17:49.

Change

Previous filing in this sequence was filed on 18 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRON transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +90,720
Change %
Price: $0.000000
Shares after: 90,720
Date: 18 Oct 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 90,720
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents the right to receive one share of Gemini Therapeutics, Inc. common stock.

Footnote F2

Thirty-three percent (33%) of the Restricted Stock Units shall vest upon the achievement of a clinical milestone, and the remaining sixty-seven percent (67%) of the Restricted Stock Units shall vest on the one (1)-year anniversary of the achievement of this clinical milestone.